Prof. Emad Elazazy

PhD, PharmD, Professor of Governance and Pharmaceutical Practices, Egypt | Egypt

Works as professor of governance practices and Chief Executive Officer of Arab Academy for Excellence in Governance; Research and dissertation advisor at several academic institutions, Manging Director of Arab Governance Alliance, and Senior healthcare consultant. He is also a founding member and secretary general of Egyptian Healthcare Society. Prof Elazazy has been instrumentally contributed towards substantial health and institutional systems governance theory, research, and practices in public, private and civil society, along with their functional oversight at various diligence systems on the ground. He also, enabled distinctive academic governance system assessments and research, healthcare system structuring and reforms, with their variable proficiency aspects and accompanying governance standardisation paradigms at global governance and board governance deployments. Prof Emad had BSc. in Pharmaceutical Sciences; Zagazig University, Master of Business Administration; A.U.C., Doctor of Pharmacy; Saskatchewan, Diploma in International-Economics; Cambridge, PhD in Industrial Management; Aston University, and ultimately Master of Public Administration; Birmingham University. Prof Emad as governance adviser to multifarious corporations’ executive boards, has been focusing on governance domains and methodologies for technical practices in public, and private as well as not-for-profit foundations over the last twenty years. He has directed and supported pioneering governance evolutionary directives at local, regional, and international levels. Besides, he assisted a multitude of leaders and higher executives in the road to enhancing governance codes, institutional operations and, collaborative integration in real-world and healthcare system governance and market enactments, in addition to health sector governance and restructuring contexts.

Prof. Abdullah Molokhia

PhD., Professor, Pharmaceutics, Egypt. | Egypt

Professor, Pharmaceutics Former Chairman, National Organization for Drug Control And Research, Egypt

Prof. Albert Wertheimer

PhD, MBA,Nova Southeastern University | USA

Dr. Albert Wertheimer has been active in sociobehavioral and administrative pharmacy research and education for more than 30 years. He earned a pharmacy degree at the University of Buffalo, an M.B.A. from the State University of New York at Buffalo and his Ph.D. at Purdue University. In addition, he completed a post-doctoral research fellowship in the department of social medicine at St. Thomas” Hospital Medical School of the University of London. He has directed nearly 100 Ph.D. students and more than that number of master’s students. He is the author or editor of 40 books, numerous book chapters and about 430 journal articles. He has lectured or consulted in about 75 countries, and he holds visiting professor appointments at universities in Mexico, Taiwan, Turkey, Slovenia and China. He performed pioneering work in the area of social and behavioral sciences in pharmacy and in more recent years has conducted research in pharmaco-economics, outcomes research, and health policy analysis. Prior to his appointment at NSU, he has been a professor at Temple University, dean of the Philadelphia College of Pharmacy, a researcher at Merck and Company, a vice president of First Health, Inc., a Pharmacy Benefit Manager and a professor and director of graduate studies at the University of Minnesota. Dr. Wertheimer has received many awards and recognitions including fellowships from the American Association of Pharmaceutical Scientists and the International Pharmacy Federation (FIP). He is Scheele Laureate and an honorary member of several professional societies. He has been a study section member/grant reviewer for the US NIH and for AHRQ. Current research interests include pharmaceutical counterfeiting, off label prescribing and cost:benefit studies.

Prof. Barry A. Bleidt

PhD, PharmD, RPh, FAPhA, FNPhA, Professor, Sociobehavioral and Administrative Pharmacy, USA | USA

Barry A. Bleidt, PhD, PharmD, RPh, FAPhA. Dr. Bleidt is a Professor of Sociobehavioral and Administrative Pharmacy at Nova Southeastern University College of Pharmacy. He received his BS Pharmacy from the University of Kentucky, PhD in Pharmacy Healthcare Administration from the University of Florida, and his PharmD from Xavier University of Louisiana. Barry has over forty years of professional experience in preventing drug use problems and substance misuse, looking at quality Pharmacy services, and looking towards the future of the profession. Dr. Bleidt served the past six years as Chair of the Program Committee for the Pharmacy Section of the American Public Health Association and fourteen years for the Alcohol, Tobacco, and Other Drugs Section, twenty-three years as the parliamentarian of the American Association of Colleges of Pharmacy, and twenty-one years as the Director of Continuing Pharmacy Education for the National Pharmaceutical Association. He has served as a Delegate to the United States Pharmacopoeia Convention from 1985 to 2020. Dr. Bleidt has also serves as the Coordinator of Certificate Programs at Nova Southeastern University College of Pharmacy and has been involved with the Immunization Certification Training of over 1,500 pharmacists, pharmacy interns, and student pharmacists. Dr. Bleidt has delivered over 400 presentations and published nearly fifty works. Some of his publications include the books: Clinical Research in Pharmaceutical Development, Multicultural Pharmaceutical Education, and A Guide to the Top 200 Drugs. Dr. Bleidt received the Lifetime Achievement Award from the Pharmacy Section of the American Public Health Association. (2020) He was inducted as a Fellow into the APhA Academy of Pharmaceutical Research and Science in 2015 and as a fellow in the National Pharmaceutical Association (NPhA) in 2016. He received the 2013 Chauncey I Cooper Award (the highest honor bestowed by NPhA), 2007 Award for Innovative and Exemplary Contributions to the NPhA Foundation, the Ilene B. Stiff Local Association President’s Award as the leader of the Virginia Pharmacists Association Local Association of the Year (2001), the James M. Tyson Award (2nd Highest Honor from NPhA (2001); and the American Public Health Association Leadership Award from the Alcohol, Tobacco, and Other Drugs Section (2000). He currently resides in Ft. Lauderdale, Florida. "

Dr. Ibrahim Al-Khars

MS, MBA, Managing Director, Business Development Manager and Senior Consultant for People & Business Development Center, KSA | Saudi Arabia

Dr. Ibrahim Al-Khars is working as Managing Director, Business Development Manager and Senior Consultant for People & Business Development Center, Dammam, Saudi Arabia. Dr. Al-Khars has a Master in Applied Business Research from Swiss Business School, Switzerland; a Master in Business Administration specialized in International Business from the University of Florida, USA and a special diploma degree in new venture creation from the same university. He received a Bachelor degree in Pharmaceutical Science from King Saud University, Riyadh, Saudi Arabia with honor and Master Degree in Clinical Pharmacy from the same university. His academic history includes a Specialty Residency in Pharmacy Practice Management at Detroit Receiving Hospital and Wayne State University, Detroit, Michigan. His research interests include health care quality improvement, health care reform, the economic evaluation of treatment strategies, health care educational system and technologies, and pharmacy practice management. In addition to his teaching and management activities, Dr. Al-Khars has conducted many presentations, executive seminars and management development programs in different countries including Saudi Arabia, USA, Germany, Malaysia, Lebanon, Oman, Egypt, and United Arab Emirates.

Mr. Jerry Yik

MPubPol, Head of Policy and Advocacy, SHPA, | Australia

Jerry leads SHPA’s diverse policy and advocacy activities, highlighting health and pharmacy policy issues to the relevant stakeholders including parliamentarians, government departments, regulatory bodies, clinical and safety agencies. Harnessing member expertise, SHPA's Policy and Advocacy team demonstrates the continuing expertise, innovation and high standard the hospital pharmacy sector sets, as well as the challenges faced by the sector to provide high quality, safe, equitable and accessible pharmacy services to Australian patients in all healthcare settings.

Dr. John Bell

FPS FRPharmS FACPP MSHP, Corporate Relations Consultant to the Pharmaceutical Society of Australia (PSA) & Advisor to the Pharmacy Self Care program, PSA, | Australia

John Bell is a Practitioner/Teacher in Primary Health Care and Professional Services at the Graduate School of Health, University of Technology Sydney. He is also Corporate Relations Consultant to the Pharmaceutical Society of Australia (PSA) and Principal Adviser to PSA’s Pharmacy Self Care Program. John has a community pharmacy practice in the eastern suburbs of Sydney John is a former National President of the PSA and President of the Australian College of Pharmacy Practice. He was Vice President of the Federation Internationale Pharmaceutique (FIP) from 2006 to 2014; and formerly President (1999-2003) and subsequently Secretary (2003-2007) of the Commonwealth Pharmacists Association (CPA). He is currently a member of the Global Pain Faculty and of the Global Respiratory Infection Partnership – international multidisciplinary groups established to address, respectively, the issues of pain management and of antibiotic stewardship. In 2021 John was appointed the inaugural Chair of the Australian Self-Care Alliance

Prof. Robert Sindelar,

PhD, FCAHS, Professor and Former Dean, Faculty of Pharmaceutical Sciences, The University of British Columbia, Canada | Canada

"Professor Robert D. Sindelar, Ph.D., FFIP, FCAHS Dr. Sindelar is a Professor and Dean Emeritus, Faculty of Pharmaceutical Sciences, University of British Columbia (UBC). Dr. Sindelar is also an elected fellow of the Canadian Academy of Health Sciences, and an elected fellow of the International Pharmaceutical Federation (FIP). Currently, he serves as the Chair of the FIP “Global Pharmacy Observatory Data & Intelligence Presidential Commission, to provide strategic advice on the development of the Global Pharmaceutical Observatory working with FIP stakeholders including WHO. He is also the Head of Pharmaceutical Sciences, the Athens Institute for Education and Research. Professor Sindelar previously served as Vice President of Innovation, Research & Academic Affairs at Providence Health Care (PHC), President of the PHC Research Institute and Associate Dean Research in the UBC Faculty of Medicine (2013-2016). He is a founder of the Centre for Drug Research and Development (formerly CDRD, now called adMare BioInnovations), a national not-for-profit drug development and commercialization centre. Also, he has served as President of the Global Drug Commercialization Centre (GDCC)-China, and Vice President, GDCC-Worldwide (2017-2019), a translational medicine endeavor that facilitates the innovative development of healthcare initiatives. In these various roles, he continues to contribute to health science research, health policy development, team-building, international partnerships, as well as strategic innovations. Dr. Sindelar completed a M.S. degree and a Ph.D. in Medicinal Chemistry and Natural Products at the University of Iowa School of Pharmacy. His research expertise is in medicinal chemistry, computer-aided drug discovery, and pharmaceutical biotechnology. He is the recipient of several School and University-wide teaching honors and has co-edited 5 editions of the highly successful textbook entitled “Pharmaceutical Biotechnology: Fundamentals and Applications.” "

Prof. Peter Pitts

President and Co-Founder, Center for Medicine in the Public Interest, | USA

Peter Pitts is President and co-founder of the Center for Medicine in the Public Interest. He also serves as a Visiting Professor at University of Paris School of Medicine. Pitts lives in New York City Professor Pitts is a former member of the United States Senior Executive Service and Associate Commissioner of the US Food & Drug Administration where he served as senior communications and policy adviser to the Commissioner. He supervised FDA's Office of Public Affairs, Office of the Ombudsman, Office of Special Health Issues, Office of Executive Secretariat, and Advisory Committee Oversight and Management. He served on the agency’s obesity working group and counterfeit drug taskforce. He is a member of the Council for International Organizations of Medical Sciences (CIOMS) Expert Working Group to help advance patient involvement in the development and safe use of medicines. (CIOMS is an international, non-governmental, non-profit organization established jointly by WHO and UNESCO in 1949.) He is the lead author of many professional peer reviewed publications including the Lancet, Therapeutic Innovation and Regulatory Science, and Nature Biotechnology. He is an Associate Editor of Therapeutic Innovation & Regulatory Science (the official DIA journal), a member of the External Advisory Board, IMS Institute for Healthcare Informatics in Asia, Executive Advisory Board, the Galien Foundation, Editorial Advisory Board, Food and Drug Policy Forum, Advisory Board, Journal of Commercial Biotechnology and a member of the Editorial Advisory Board of The Patient Magazine. His comments and commentaries on health care policy issues regularly appear in The New York Times, The Los Angeles Times, The Washington Post, The Wall Street Journal, The Financial Times, Health Affairs, Time, Newsweek, The Boston Globe, The Washington Times, The Chicago Tribune, The San Francisco Examiner, Investor’s Business Daily, The Baltimore Sun, The Economist, The Lancet, Nature Biotechnology, BioCentury, The Journal of Commercial Biotechnology, the BBC World Service, Fox News, CNBC, Bloomberg, The PBS NewsHour, NBC Dateline, Sky News, La Stampa. L’Opinion, The Daily Show with John Stewart, among others. He has given healthcare policy lectures throughout Europe, Canada, and the United States, as well as in Russia, China, Hong Kong, Taiwan, India, the Philippines, Malaysia, Saudi Arabia, Lebanon, Oman, Israel, Turkey, The United Arab Emirates, Kuwait, Qatar, Jordan, Kenya, South Africa, Egypt, Algeria, Ukraine, Thailand, Japan, Brazil, Mexico, Vietnam, Indonesia, Singapore, Panama, Costa Rica, Argentina, and Columbia. His new book, The Next Normal discusses how we can apply the lessons learned from COVID-19 to advance other areas of healthcare. He is also the author of two other books on advancing America’s health, The Value Equation and Commonsense Healthcare Policy for Commonsense Americans. He is also the author of Become Strategic or Die, widely recognized as a cutting edge study of how leadership, in order to be successful over the long term, must be combined with strategic vision and ethical practice. He is the editor of Coincidence or Crisis, a discussion of global prescription medicine counterfeiting and Physician Disempowerment: A Transatlantic Malaise. He has also served as an adjunct professor at Indiana University’s School of Public and Environmental Affairs and Butler University.

Dr. Majid R. Tanas

PharmD, MHA, MS, FASHP, Vice President of Pharmacy & Chief Pharmacy Officer for Legacy Health. | USA

Dr. Tanas has sought to help others in the profession by mentoring, speaking at conferences, and elevating pharmacy practice at the state and national level. In 2009, Dr. Tanas helped lead the remediation of Oregon Board of Pharmacy findings of non-compliance for Remote IV Dispensing. Through this effort, statutes for Oregon were developed to support Remote IV Dispensing - many of which became a model for others to reference. By this endeavor, oncology-trained Health-System Pharmacists remotely managed Pharmacy Technicians in cleanrooms across 100 miles of freeway. This model allowed Pharmacy Technicians to practice at a higher level as they were able to function independently. As a part of Specialty Pharmacy expansion within Oregon, Dr. Tanas spearheaded the Specialty Pharmacy team to expand critical specialty medications to Oregonians by achieving URAC accreditation, building a specialty program, and developing ambulatory practices to reach more patients. In 2015, The National Institutes of Health Clinical Center had significant FDA 483 findings in their cleanroom. This impact halted much of NIH-sponsored research. After a nationwide search, Dr. Tanas was selected to become the Chief of Pharmacy due to his cleanroom and remediation expertise. During his tenure, he established a team to address significant operational changes to modernize current regulatory practice standards, design the first Health-System cGMP compliant 503A cleanroom, increase the department FTE by nearly double, and expand resources for research. In the midst of a challenging transition, Dr. Tanas made the difficult decision to issue a nationwide recall for medications due to quality concerns. His leadership ultimately led the NIH Clinical Center to initiate a medication safety and quality program and instituted daily organization-wide safety huddles. Currently, Dr. Tanas leads a multi-hospital health system at Legacy Health Pharmacy Services to elevate their cleanroom and regulatory practices. He has directed remodels at five hospitals across the region, upgraded to automated dispensing cabinets for safer medication delivery systems, established a technician-led compliance team for diversion prevention, achieved URAC/ACHC Specialty Pharmacy accreditation, and expanded 340b outpatient clinic services. During the pandemic, his leadership and collaboration with adjoining health systems across the region resulted in the nation's fifth-largest mass vaccination site. Throughout his career, Dr. Tanas has exemplified a commitment to patient safety and compliance by creating unique systems to deliver pharmaceutical care. He continues to give back to the pharmacy community by mentoring student and resident pharmacists to challenge their paradigm around patient care. In addition, he creates opportunities for both technicians and pharmacists to advance their careers in unique care models.